Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer

Cancer

Volumn 117, Issue 14, 2011, Pages 3193-3200

  Donnem, Tom ^a,b   Lonvik, Kenneth ^a,b   Eklo, Katrine ^a,b   Berg, Thomas ^a,b   Sorbye, Sveinung W ^a,b   Al Shibli, Khalid ^a,c   Al Saad, Samer ^a,b   Andersen, Sigve ^a,b   Stenvold, Helge ^a,b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 126; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; ORGAN SPECIFICITY; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959954361     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25907     Document Type: Article

References (26)

1. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28: 1721-1726.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
3. Esquela-Kerscher A, Johnson SM, Bai L, et al. Post-embryonic expression of C. elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive system. Dev Dyn. 2005; 234: 868-877. (Pubitemid 41741159)
4. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-838. (Pubitemid 40839735)
5. Heusschen R, van GM, Griffioen AW, Thijssen VL., MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. Biochim Biophys Acta. 2010; 1805: 87-96.
6. Hanahan D, Weinberg RA., The hallmarks of cancer. Cell. 2000; 100: 57-70. (Pubitemid 30046295)
7. Fish JE, Srivastava D., MicroRNAs: opening a new vein in angiogenesis research. Sci Signal. 2009; 2:p e1.
8. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008; 3: e2557.
9. Negrini M, Calin GA., Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008; 10: 203.
10. Li XM, Wang AM, Zhang J, Yi H., Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol. 2010 Jul 31 (E-pub ahead of print).
11. Feng R, Chen X, Yu Y, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010; 298: 50-63.
12. Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun. 2008; 373: 607-612.
13. Liu B, Peng XC, Zheng XL, Wang J, Qin YW., MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009; 66: 169-175.
14. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9: 189-198. (Pubitemid 43357945)
15. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009; 69: 5776-5783.
16. Goldstraw P., The 7th edition of TNM in Lung Cancer: what now? J Thorac Oncol. 2009; 4: 671-673.
17. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res. 2007; 13: 6649-6657. (Pubitemid 350206800)
18. World Health Organization. Histological typing of lung and pleural tumours. 3rd ed. Geneva, Switzerland: Springer-Verlag; 1999.
19. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD., A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc. 2009; 4: 107-115.
20. Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT, Bremnes RM., VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer. 2009; 63: 277-283.
21. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, Busund LT, Bremnes RM., Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010; 116: 4318-4325.
22. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007; 7: 36.
23. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007; 13: 1668-1674. (Pubitemid 47481675)
24. Hu Y, Correa AM, Hoque A, et al. Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2011; 128: 132-143.
25. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550. (Pubitemid 44917502)
26. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008; 15: 261-271.